Fairmount Funds holds 16.5% of Crescent Biopharma (CBIO) after July 2026 deal

Rhea-AI Filing Summary

Crescent Biopharma, Inc. received an updated ownership disclosure from Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., and principals Peter Harwin and Tomas Kiselak. The group reports beneficial ownership of 6,593,385 Ordinary Shares of Crescent Biopharma, representing 16.50% of the Ordinary Shares outstanding, based on 39,960,923 Ordinary Shares as of July 16, 2026. This position includes 3,601,316 Ordinary Shares, 2,890,000 Ordinary Shares issuable upon conversion of 2,890 Series A Preferred Shares, and 102,069 Ordinary Shares issuable upon exercise of Pre-Funded Warrants, while excluding 2,191,968 additional warrant shares due to beneficial ownership limits.

On July 16, 2026, Fairmount Healthcare Fund II L.P. purchased 853,450 Ordinary Shares at $14.50 per share and Pre-Funded Warrants to purchase 525,897 Ordinary Shares at $14.499 each in an underwritten public offering, for an aggregate purchase price of $20,000,005.60, using working capital. The securities were acquired for investment purposes.

The reporting persons entered into a 60-day Lock-Up Agreement following the final prospectus supplement, restricting sales of Crescent Biopharma securities without underwriters’ consent. The Pre-Funded Warrants carry a $0.001 exercise price, are immediately exercisable, and do not expire, but are subject to a 9.99% beneficial ownership limitation, which can be adjusted up to 19.99% with a 61-day delay. Conversion of the Series A Preferred Shares is capped at 19.99%, automatically dropping to 9.99% if Fairmount and affiliates’ ownership falls to 9.0% or less. Harwin also holds options for 9,023 Ordinary Shares at $15.30 per share that vested on June 2, 2026, but he disclaims beneficial ownership in favor of Fairmount-managed funds.

Key Figures

Beneficial ownership: 6,593,385 Ordinary Shares Ownership percentage: 16.50 % Direct Ordinary Shares held: 3,601,316 Ordinary Shares +5 more

8 metrics

Beneficial ownership 6,593,385 Ordinary Shares Voting and dispositive power over Crescent Biopharma Ordinary Shares

Ownership percentage 16.50 % Portion of Crescent Biopharma Ordinary Shares outstanding represented by the reported position

Direct Ordinary Shares held 3,601,316 Ordinary Shares Ordinary Shares directly held as part of the Fairmount group’s position

Series A conversion shares 2,890,000 Ordinary Shares Ordinary Shares issuable upon conversion of 2,890 Series A Preferred Shares

Excluded warrant shares 2,191,968 Ordinary Shares Ordinary Shares underlying Pre-Funded Warrants excluded due to beneficial ownership limitation

Shares outstanding baseline 39,960,923 Ordinary Shares Ordinary Shares outstanding as of July 16, 2026 used to calculate ownership

Aggregate offering purchase $20,000,005.60 Total paid for 853,450 Ordinary Shares and 525,897 Pre-Funded Warrants on July 16, 2026

Offering share price $14.50 per share Price per Crescent Biopharma Ordinary Share in the July 16, 2026 underwritten offering

Key Terms

beneficial ownership limitation, Pre-Funded Warrants, Series A Preferred Shares, underwritten public offering, +2 more

6 terms

beneficial ownership limitation financial

"The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 9.99%"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

Pre-Funded Warrants financial

"Pre-Funded Warrants to purchase up to 102,069 Ordinary Shares, the exercise of which is subject"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Series A Preferred Shares financial

"2,890,000 Ordinary Shares issuable upon conversion of 2,890 Series A Preferred Shares"

Series A preferred shares are an early-stage class of ownership sold to investors that gives them special protections and payment priority over regular common stock. Think of them as a safer seat on a bus: if the company earns money or is sold, holders get paid before ordinary shareholders, and they often can convert to common shares later to share upside; that mix of safety and growth potential helps investors manage risk and reward.

underwritten public offering financial

"purchased a total of 853,450 Ordinary Shares and Pre-Funded Warrants ... in an underwritten public offering"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

Lock-Up Agreement financial

"the Reporting Persons entered into a customary lock-up letter agreement (the "Lock-Up Agreement")"

A lock-up agreement is a contract that prevents company insiders and early investors from selling their shares for a fixed period after a stock sale, often after an initial public offering. It matters to investors because it temporarily limits the number of shares that can hit the market, which can keep the share price steadier; when the lock-up ends, a sudden increase in available shares can create extra volatility, revealing insiders’ confidence or lack thereof.

dispositive power financial

"Fairmount is the investment manager to Fund II and has voting and dispositive power over Ordinary Shares"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/20/2026 - 05:30 PM Accepted by SEC EDGAR 07/20/2026 - 05:30 PM Learn about SEC filing dates

FAQ

How much of Crescent Biopharma (CBIO) do the Fairmount entities now own?

The Fairmount entities report beneficial ownership of 6,593,385 Ordinary Shares of Crescent Biopharma, representing 16.50% of the Ordinary Shares outstanding, calculated using 39,960,923 Ordinary Shares outstanding as of July 16, 2026.

What securities make up the Fairmount group’s 6,593,385-share CBIO position?

The group’s position includes 3,601,316 Ordinary Shares, 2,890,000 Ordinary Shares issuable from 2,890 Series A Preferred Shares, and 102,069 Ordinary Shares from Pre-Funded Warrants, while excluding 2,191,968 warrant shares blocked by a beneficial ownership limitation.

What did Fairmount Healthcare Fund II L.P. buy in the July 16, 2026 CBIO offering?

On July 16, 2026, Fairmount Healthcare Fund II L.P. bought 853,450 Ordinary Shares at $14.50 per share and Pre-Funded Warrants for 525,897 shares at $14.499 each, for a total purchase price of $20,000,005.60 in an underwritten public offering.

What are the key terms of Crescent Biopharma (CBIO) Pre-Funded Warrants held by Fairmount?

The Pre-Funded Warrants have a $0.001 exercise price, are immediately exercisable, and do not expire. Exercises are limited by a 9.99% beneficial ownership cap, which holders may adjust up to 19.99%, with increases becoming effective after 61 days.

What beneficial ownership limits apply to Fairmount’s Series A Preferred Shares in CBIO?

Conversion of Fairmount’s Series A Preferred Shares into Ordinary Shares is subject to a 19.99% beneficial ownership cap. If Fairmount and affiliates’ ownership falls to 9.0% or less, this cap automatically reduces to 9.99% of Crescent Biopharma’s outstanding Ordinary Shares.

Is there a lock-up restricting Fairmount’s sales of Crescent Biopharma (CBIO) securities?

Yes. The reporting persons entered a 60-day Lock-Up Agreement in connection with the July 16, 2026 underwritten offering, agreeing not to sell Crescent Biopharma securities without the underwriters’ consent, subject to other customary lock-up conditions.

What stock options related to CBIO does Peter Harwin hold and how are they treated?

Peter Harwin holds options for 9,023 Ordinary Shares at an exercise price of $15.30 per share, which vested on June 2, 2026. He is obligated to turn over any net proceeds to Fairmount funds and therefore disclaims beneficial ownership.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

Crescent Biopharma, Inc.

(Name of Issuer)

Ordinary Shares, $0.001 par value

(Title of Class of Securities)

G2545C104

(CUSIP Number)

Ms. Erin O'Connor
Fairmount Funds Management LLC, 200 Barr Harbor Drive, Suite 400
West Conshohocken, PA, 19428
(267) 262-5300

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/16/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): G2545C104

1

Name of reporting person

Fairmount Funds Management LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,593,385.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,593,385.00

11

Aggregate amount beneficially owned by each reporting person

6,593,385.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

16.50 %

14

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person:

The securities include (a) 3,601,316 ordinary shares, $0.001 par value per share (the "Ordinary Shares"), 2,890,000 Ordinary Shares issuable upon conversion of 2,890 shares of Series A non-voting convertible preferred shares, par value $0.001 per share (the "Series A Preferred Shares"), and 102,069 Ordinary Shares issuable upon exercise of Pre-Funded Warrants directly held by Fairmount Healthcare Fund II L.P. ("Fund II") and exclude (b) 2,191,968 Ordinary Shares issuable upon exercise of Pre-Funded Warrants directly held by Fund II due to the application of a beneficial ownership limitation. The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 9.99% of the outstanding Ordinary Shares and the exercise of the Series A Preferred Shares is subject to a beneficial ownership limitation of 19.99%. At such time as Fairmount Funds Management LLC ("Fairmount") and its affiliates beneficially own 9.0% or less of the Ordinary Shares, the beneficial ownership limitation with respect to the Series A Preferred Shares will automatically reduce to 9.99%. Row 13 is based on 39,960,923 Ordinary Shares outstanding as of July 16, 2026, consisting of (i) 36,959,831 Ordinary Shares outstanding as of July 16, 2026, as reported in the Company's prospectus supplement filed pursuant to Rule 424(b)(5) dated July 14, 2026, (ii) 9,023 Ordinary Shares underlying options that are currently exercisable or will be exercisable within 60 days of the date of this filing by the Reporting Persons, (iii) 102,069 Ordinary Shares underlying the Pre-Funded Warrants owned by the Reporting Persons, subject to the beneficial ownership limitation, and (iv) 2,890,000 Ordinary Shares underlying the 2,890 shares of Series A Preferred Shares owned by the Reporting Persons.

SCHEDULE 13D

CUSIP Number(s): G2545C104

1

Name of reporting person

Fairmount Healthcare Fund II L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,593,385.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,593,385.00

11

Aggregate amount beneficially owned by each reporting person

6,593,385.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

16.50 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

The securities include (a) 3,601,316 Ordinary Shares, 2,890,000 Ordinary Shares issuable upon conversion of 2,890 Series A Preferred Shares, and 102,069 Ordinary Shares issuable upon exercise of Pre-Funded Warrants directly held by the Reporting Person and exclude (b) 2,191,968 Ordinary Shares issuable upon exercise of Pre-Funded Warrants, due to the application of the beneficial ownership limitation. The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 9.99% of the outstanding Ordinary Shares and the exercise of the Series A Preferred Shares is subject to a beneficial ownership limitation of 19.99%. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the Ordinary Shares, the beneficial ownership limitation with respect to the Series A Preferred Shares will automatically reduce to 9.99%. Row 13 is based on 39,960,923 Ordinary Shares outstanding as of July 16, 2026, consisting of (i) 36,959,831 Ordinary Shares outstanding as of July 16, 2026, as reported in the Company's prospectus supplement filed pursuant to Rule 424(b)(5) dated July 14, 2026, (ii) 9,023 Ordinary Shares underlying options that are currently exercisable or will be exercisable within 60 days of the date of this filing by the Reporting Persons, (iii) 102,069 Ordinary Shares underlying the Pre-Funded Warrants owned by the Reporting Persons, subject to the beneficial ownership limitation, and (iv) 2,890,000 Ordinary Shares underlying the 2,890 shares of Series A Preferred Shares owned by the Reporting Persons.

SCHEDULE 13D

CUSIP Number(s): G2545C104

1

Name of reporting person

Peter Harwin

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 9,023.00
8	Shared Voting Power 6,593,385.00
9	Sole Dispositive Power 9,023.00
10	Shared Dispositive Power 6,593,385.00

11

Aggregate amount beneficially owned by each reporting person

6,602,408.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

16.52 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The securities include (a) 9,023 Ordinary Shares issuable upon the exercise of options that are currently exercisable or will be exercisable within 60 days of the date of this filing held directly by Mr. Harwin*, (b) Fund II's direct holdings of (i) 3,601,316 Ordinary Shares, (ii) 2,890,000 Ordinary Shares issuable upon conversion of 2,890 Series A Preferred Shares, and (iii) 102,069 Ordinary Shares issuable upon exercise of Pre-Funded Warrants directly held by the Reporting Person and (c) exclude 2,191,968 Ordinary Shares issuable upon exercise of Pre-Funded Warrants due to the application of the beneficial ownership limitation. The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 9.99% of the outstanding Ordinary Shares and the exercise of the Series A Preferred Shares is subject to a beneficial ownership limitation of 19.99%. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the Ordinary Shares, the beneficial ownership limitation with respect to the Series A Preferred Shares will automatically reduce to 9.99%. Row 13 is based on 39,960,923 Ordinary Shares outstanding as of July 16, 2026, consisting of (i) 36,959,831 Ordinary Shares outstanding as of July 14, 2026, as reported in the Company's prospectus supplement filed pursuant to Rule 424(b)(5) dated July 10, 2026, (ii) 9,023 Ordinary Shares underlying options that are currently exercisable or will be exercisable within 60 days of the date of this filing by the Reporting Persons, (iii) 102,069 Ordinary Shares underlying the Pre-Funded Warrants owned by the Reporting Persons, subject to the beneficial ownership limitation, and (iv) 2,890,000 Ordinary Shares underlying the 2,890 shares of Series A Preferred Shares owned by the Reporting Persons. * Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the options for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock.

SCHEDULE 13D

CUSIP Number(s): G2545C104

1

Name of reporting person

Tomas Kiselak

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

SLOVAKIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,593,385.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,593,385.00

11

Aggregate amount beneficially owned by each reporting person

6,593,385.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

16.50 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

The information in the "Comments" to the cover page for Fairmount Funds Management LLC above is hereby incorporated by reference.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, $0.001 par value
(b)	Name of Issuer: Crescent Biopharma, Inc.
(c)	Address of Issuer's Principal Executive Offices: 300 Fifth Avenue, Waltham, MASSACHUSETTS , 02451.
Item 1 Comment: This Amendment No. 2 amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on June 23, 2025 as amended by Amendment No. 1 filed with the SEC on December 8, 2025 (as amended, the "Statement" or the "Schedule 13D") by the Reporting Persons with respect to the Ordinary Shares of the Company. Unless otherwise defined herein, capitalized terms used in this Amendment No. 2 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 of the Statement is hereby amended and supplemented as follows: In aggregate, the Reporting Persons have voting and dispositive power over 6,593,385 Ordinary Shares of the Company, which is comprised of (a) 3,601,316 Ordinary Shares, (b) Pre-Funded Warrants to purchase up to 102,069 Ordinary Shares, the exercise of which is subject to a beneficial ownership limitation of 9.99% of the outstanding Ordinary Shares (and therefore excluding 2,191,968 Ordinary Shares issuable upon exercise of the Pre-Funded Warrants in excess of the beneficial ownership limitation), and (c) 2,890,000 Ordinary Shares issuable upon conversion of 2,890 Series A Preferred Shares, the conversion of which is subject to a beneficial ownership limitation of 19.99% of the outstanding Ordinary Shares. On July 16, 2026, Fund II purchased a total of (i) 853,450 Ordinary Shares and (ii) Pre-Funded Warrants to purchase up to 525,897 Ordinary Shares for an aggregate purchase price of $20,000,005.60 in an underwritten public offering (the "Offering"). The securities were purchased with working capital.
Item 4.	Purpose of Transaction
	Item 4 of the Statement is hereby amended and supplemented as follows: Fund II purchased the Ordinary Shares and Pre-funded Warrants referenced in Item 3 for investment purposes. Lock-Up Agreement In connection with the Company's underwritten public offering of Ordinary Shares and Pre-Funded Warrants that closed on July 16, 2026, the Reporting Persons entered into a customary lock-up letter agreement (the "Lock-Up Agreement") with Jefferies LLC and TD Securities (USA) LLC acting as the Representatives (collectively, the "Representatives") of the underwiters party to to an underwriting agreement with the Company. Pursuant to the Lock-Up Agreement, the Reporting Persons agreed to refrain from selling shares of the Company's securities without the consent of the Representatives, and other customary lock-up conditions, for a period of 60 days following the date of the final prospectus supplement for the offering. The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the Form of Lock-Up Agreement, which is filed as Exhibit 99.2 to this Schedule 13D and incorporated herein by reference. Pre-Funded Warrants The Pre-Funded Warrants purchased by Fund II in the offering have an exercise price of $0.001, are immediately exercisable at any time after the date of issuance and will not expire. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99%, as applicable, of the number of Ordinary Shares outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage to a percentage not in excess of 19.99% by providing notice to the Company. Any increase in the percentage will not be effective until the 61st day after such notice is delivered. The foregoing description of the Pre-Funded Warrants does not purport to be complete and is qualified in its entirety by reference to the form of Pre-Funded Warrant, which is filed as Exhibit 99.3 hereto.
Item 5.	Interest in Securities of the Issuer
(a)	The information in rows 11 and 13 of each of the cover pages (including the explanatory note in the "Comments") of this Amendment No. 2 is incorporated by reference herein. In aggregate, the Reporting Persons' securities include (a) 3,601,316 Ordinary Shares, (b) 9,023 shares of Common Stock issuable upon the exercise of options held by the Reporting Persons that are currently exercisable or will be exercisable within 60 days of the date of this filing, (c) 2,890,000 Ordinary Shares issuable upon conversion of 2,890 shares of Series A Preferred Shares, and (d) 102,069 Ordinary Shares issuable upon exercise of Pre-Funded Warrants. The securities exclude 2,191,968 Ordinary Shares issuable upon exercise of Pre-Funded Warrants directly held by Fund II due to application of the beneficial ownership limitation. The exercise of the Pre-Funded Warrants is subject to a beneficial ownership limitation of 9.99% of the outstanding Ordinary Shares and the conversion of the Series A Preferred Shares is subject to a beneficial ownership limitation of 19.99%. At such time as Fairmount and its affiliates beneficially own 9.0% or less of the Ordinary Shares, the beneficial ownership limitation with respect to the Series A Preferred Shares will automatically reduce to 9.99%.
(b)	The information in rows 7 through 10 of each of the cover pages of this Amendment No. 2 is incorporated by reference herein.
(c)	Item 5(c) of the Schedule 13D is hereby supplemented as follows: On July 16, 2026, Fund II purchased in the Offering a total of (i) 853,450 Ordinary Shares at a price of $14.50 per share and (ii) Pre-Funded Warrants to purchase 525,897 Ordinary Shares at a purchase price of $14.499 per Pre-Funded Warrant, which represents the per share purchase price of the Ordinary Shares less the $0.001 per share exercise price for each Pre-Funded Warrant, for an aggregate purchase price of $20,000,005.60. On June 2, 2026, Mr. Harwin's stock options to purchase 9,023 Ordinary Shares at an exercise price of $15.30 per share, received as compensation for his service as a director of the Company, vested in full and became exercisable.
(d)	Fairmount is the investment manager to Fund II and has voting and dispositive power over Ordinary Shares held on behalf of Fund II.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The information set forth in Item 4 of this Amendment No. 2 is incorporated herein by reference.
Item 7.	Material to be Filed as Exhibits.
	99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 of the Reporting Persons' Schedule 13D filed with the SEC on December 8, 2025) 99.2 Lock-Up Agreement (incorporated by reference to Exhibit A to the Underwriting Agreement filed as Exhibit 1.1 of the Company's Form 8-K filed with the SEC on July 15, 2026) 99.3 Form of Pre-Funded Warrant (incorporated herein by reference to Exhibit 4.1 of the Company's Current Report on Form 8-K filed on July 15, 2026)

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Fairmount Funds Management LLC

Signature:	/s/ Peter Harwin
Name/Title:	Peter Harwin, Managing Member
Date:	07/20/2026

Signature:	/s/ Tomas Kiselak
Name/Title:	Tomas Kiselak, Managing Member
Date:	07/20/2026

Fairmount Healthcare Fund II L.P.

Signature:	/s/ Peter Harwin
Name/Title:	Peter Harwin, Managing Member
Date:	07/20/2026

Signature:	/s/ Tomas Kiselak
Name/Title:	Tomas Kiselak, Managing Member
Date:	07/20/2026

Peter Harwin

Signature:	/s/ Peter Harwin
Name/Title:	Peter Harwin
Date:	07/20/2026

Tomas Kiselak

Signature:	/s/ Tomas Kiselak
Name/Title:	Tomas Kiselak
Date:	07/20/2026